Magic mushroom compound shows promise for Hard-to-Treat depression
NCT ID NCT05220410
First seen Jan 09, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study looked at whether a single 25mg dose of psilocybin, given in a supportive setting, is safe and tolerable for adults with treatment-resistant depression and ongoing suicidal thoughts. Twenty participants aged 18 to 65 who had not responded to at least two depression medications were enrolled. The goal was to see if the treatment could reduce suicidal thinking and depression severity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUICIDAL IDEATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sheppard Pratt Health System
Baltimore, Maryland, 21204, United States
Conditions
Explore the condition pages connected to this study.